Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the STACK-on to ENOXaparin (STACKENOX) study

American Heart Journal

Volumn 158, Issue 2, 2009, Pages 177-184

  Drouet, Ludovic ^a,b   Bal dit Sollier, Claire ^a   Martin, Jack ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BRYN MAWR HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A ANTIBODY; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROTEIN ANTIBODY; PROTHROMBIN A ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; BLOOD COAGULATION; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; WHOLE BLOOD COAGULATION TIME;

EID: 67650517543     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.05.022     Document Type: Article

References (35)

1. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337 (1997) 447-452
2. Antman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 100 (1999) 1602-1608
3. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 100 (1999) 1593-1601
4. Murphy S.A., Gibson C.M., Morrow D.A., et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28 (2007) 2077-2086
5. Cohen M., Diez J.E., Levine G.N., et al. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report-III. J Invasive Cardiol 12 (2007) 525-538
6. Stommel M., Olomu A., Holmes-Rovner M., et al. Changes in practice patterns affecting in-hospital and post-discharge survival among ACS patients. BMC Health Serv Res 6 (2006) 140
7. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
8. Antman E.M., Hand M., Armstrong P.W., et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117 (2008) 296-329
9. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
10. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
11. Hulot J.S., Montalescot G., Lechat P., et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77 (2005) 542-552
12. Ferguson J.J., Dougherty K.G., Gaos C.M., et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 23 (1994) 1061-1065
13. Al Dieri R., Alban S., Béguin S., et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2 (2004) 1395-1401
14. Montalescot G., Collet J.P., Tanguy M.L., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110 (2004) 392-398
15. Collet J.P., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103 (2001) 658-663
16. Kereiakes D.J., Grines C., Fry E., et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 13 (2001) 272-278
17. Choussat R., Montalescot G., Collet J.P., et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 40 (2002) 1943-1950
18. Bijsterveld N.R., Moons A.H., Meijers J.C., et al. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimenof low-molecular-weight heparin in the initial treatment of acutecoronary syndromes. J Am Coll Cardiol 42 (2003) 424-427
19. Sanchez-Pena P., Hulot J.S., Urien S., et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 60 (2005) 364-373
20. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneouscoronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007) 2238-2246
21. Brodin E., Seljeflot I., Arnesen H., et al. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res 123 (2009) 573-579
22. Hemker H.C., Al Dieri R., De Smedt E., et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96 (2006) 553-561
23. Hemker H.C., Giesen P., Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
24. Montalescot G., Cohen M., Salette G., et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneouscoronary intervention: insights from the STEEPLE trial. Eur Heart J 29 (2008) 462-471
25. Levine G.N., and Ferrando T. Degree of anticoagulation after onesubcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromesundergoing early percutaneous coronary intervention. J Thromb Thrombolysis 17 (2004) 167-171
26. Martin J.L., Fry E.T., Sanderink G.J., et al. Reliable anticoagulationwith enoxaparin in patients undergoing percutaneous coronaryintervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61 (2004) 163-170
27. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 Focused Updateof the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117 (2008) 261-295
28. Young J.J., Kereiakes D.J., and Grines C.L. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invasive Cardiol 12 Suppl E (2000) E14-E18 [discussion E25-8]
29. Despotis G.J., Summerfield A.L., Joist J.H., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 (1994) 1076-1082
30. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 29 (1997) 1474-1482
31. Popma J.J., Weitz J., Bittl J.A., et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 114 (1998) 728S-741S
32. Cheneau E., Canos D., Kuchulakanti P.K., et al. Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. Am J Cardiol 94 (2004) 789-792
33. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 (2006) 1006-1017
34. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
35. White H.D., Kleiman N.S., Mahaffey K.W., et al. Efficacy andsafety of enoxaparin compared with unfractionated heparin inhigh-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary interventionin the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 152 (2006) 1042-1050